Skip to main content

$0.005 (0%)

High

$0.01

Low

$0.01

Trades

3

Turnover

$2,010

Volume

402,075
30 June 2023 at 11:45am
Register to track AVE and receive email alerts.
Subject
AVE Ann: Positive results from AVE's topical CBD pain study

AVE Ann: Dosing begins in topical CBD pain study

AVE Ann: Appendix 4G and Corporate Governance Statement

AVE Ann: Appendix 4E and Annual Report 31 December 2021

AVE Ann: AVE license agreement for US recreational cannabis market

AVE Ann: December 2021 Quarterly Activities Report & Appendix 4C

AVE Ann: Application for quotation of securities - AVE

AVE Ann: Section 708A Cleansing Statement

AVE Ann: AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis

AVE Ann: Positive results from Avecho's Phase I trial of CBD soft-gel

AVE Ann: September 2021 Quarterly Activities Report & Appendix 4C

AVE Ann: Topical CBD pain study with Lambert Initiative approved

AVE Ann: Dosing begins in Phase I PK trial testing CBD soft-gel

AVE Ann: Phase I clinical trial testing CBD product-enrolment begins

AVE Ann: Change of Director's Interest Notice

AVE Ann: Notification of cessation of securities - AVE

AVE Ann: Appendix 4D and Half-year Financial Report

AVE Ann: June 2021 Quarterly Activities Report & Appendix 4C

AVE Ann: Application for quotation of securities - AVE

AVE Ann: Section 708A Cleansing Statement

AVE Ann: Avecho to Present New CBD Data at GCI Virtual Summit

AVE Ann: Change of Director's Interest Notice x3

AVE Ann: Appendix 3G

AVE Ann: Final Director's Interest Notice

AVE Ann: 2021 Annual General Meeting Results

AVE Ann: Chair's Address and CEO Presentation

AVE Ann: AB Vista to explore new TPM applications for Animal Health

AVE Ann: Changes to AGM attendance protocols

AVE Ann: TGA meeting for CBD soft-gel targeting insomnia

AVE Ann: Avecho completes pharmaceutical CBD soft-gel product

AVE Ann: Resignation of Director & Withdrawal of AGM Resolution

AVE Ann: Notice of Annual General Meeting/Proxy Form

AVE Ann: March 2021 Quarterly Activities Report & Appendix 4C

AVE Ann: Avecho receives ethics approval for CBD human trial

AVE Ann: Appendix 4G and Corporate Governance Statement

AVE Ann: Annual Report - 31 December 2020

AVE Ann: Appendix 4E - Preliminary Final Report

AVE Ann: Appendix 2A - Options

AVE Ann: S708A Cleansing Notice and Appendix 2A

AVE Ann: Update - Proposed issue of Securities - AVE

AVE Ann: Proposed issue of Securities - AVE

AVE Ann: AVE receives firm commitment to raise $5.06 via placement

AVE Ann: Trading Halt

AVE Ann: December 2020 Quarterly Activities Report & Appendix 4C

AVE Ann: AVE begins Human Trial on CBD product

AVE Ann: Section 708A Cleansing Statement & Appendix 2A

AVE Ann: Grant of Unlisted Options & Appendix 3G

AVE Ann: Improved Propofol TPM Formulation Passes Toxicology Study

AVE Ann: September 2020 Quarterly Activities Report & Appendix 4C

AVE Ann: Response to ASX Price Query

Register to track AVE and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL